ASCA: Surgery Centers Receive Letters Warning About Compounded Drugs

Surgery centers have reported to ASCA that they have received letters from law firms representing drug manufacturers, warning about the use of compounded drug products over commercially produced drugs, according to an ASCA report.

ASCA has contacted the FDA to determine whether the statements in the letters are accurate. ASCA asks surgery centers receiving such letters to contact Steve Miller at This email address is being protected from spambots. You need JavaScript enabled to view it. .

Related Articles About ASC Supply Chain:
Precision Spine Receives FDA Clearance for Minimally Invasive Access System
Lutronic Receives FDA Clearance for Phototherapy System
Ethicon Initiates Recall of Select Surgiflo Hemostatic Kits

© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.